Bisphosphonate-induced atypical femoral fracture in tandem: long-term follow-up is warranted.

Mohammed Anwar HussainAneez JosephVinoo Mathew CherianAlok SrivastavaKripa Elizabeth CherianNitin KapoorThomas Vizhalil Paul

Published in: Endocrinology, diabetes & metabolism case reports (2022)

Regular screening and follow-up of patients who receive long-term bisphosphonate (BP) therapy should be done. Discontinuation of BPs does not preclude the possibility of repeated occurrence of a second AFF. Long-term BP therapy warrants regular monitoring and follow-up should an AFF occur.

Keyphrases

risk assessment
high glucose
diabetic rats
oxidative stress
mesenchymal stem cells
hip fracture
replacement therapy